163 related articles for article (PubMed ID: 24886671)
1. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.
Diouf M; Chibaudel B; Filleron T; Tournigand C; Hug de Larauze M; Garcia-Larnicol ML; Dumont S; Louvet C; Perez-Staub N; Hadengue A; de Gramont A; Bonnetain F
Health Qual Life Outcomes; 2014 May; 12():69. PubMed ID: 24886671
[TBL] [Abstract][Full Text] [Related]
2. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Chibaudel B; Bonnetain F; Tournigand C; Bengrine-Lefevre L; Teixeira L; Artru P; Desramé J; Larsen AK; André T; Louvet C; de Gramont A
Oncologist; 2011; 16(9):1228-38. PubMed ID: 21859820
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.
Jary M; Vernerey D; Lecomte T; Dobi E; Ghiringhelli F; Monnien F; Godet Y; Kim S; Bouché O; Fratte S; Gonçalves A; Leger J; Queiroz L; Adotevi O; Bonnetain F; Borg C
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):603-12. PubMed ID: 25583947
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
6. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Raimondi A; Di Maio M; Morano F; Corallo S; Lonardi S; Antoniotti C; Rimassa L; Sartore-Bianchi A; Tampellini M; Ritorto G; Murialdo R; Clavarezza M; Zaniboni A; Adamo V; Tomasello G; Petrelli F; Antonuzzo L; Giordano M; Cinieri S; Longarini R; Bergamo F; Niger M; Antista M; Peverelli G; de Braud F; Di Bartolomeo M; Pietrantonio F
Eur J Cancer; 2020 Aug; 135():230-239. PubMed ID: 32623288
[TBL] [Abstract][Full Text] [Related]
8. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
9. Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Yamaguchi K; Ando M; Ooki A; Beier F; Guenther S; von Hohnhorst P; Van Cutsem E
Clin Colorectal Cancer; 2017 Jun; 16(2):e29-e37. PubMed ID: 28081962
[TBL] [Abstract][Full Text] [Related]
10. Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
Ward P; Hecht JR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Naeim A
J Geriatr Oncol; 2014 Oct; 5(4):368-75. PubMed ID: 25002322
[TBL] [Abstract][Full Text] [Related]
11. Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location.
Golan T; Urban D; Berger R; Lawrence YR
Cancer; 2013 Aug; 119(16):3084-91. PubMed ID: 23720150
[TBL] [Abstract][Full Text] [Related]
12. Can patient satisfaction with quality of life predict survival in advanced colorectal cancer?
Lis CG; Gupta D; Granick J; Grutsch JF
Support Care Cancer; 2006 Nov; 14(11):1104-10. PubMed ID: 16819630
[TBL] [Abstract][Full Text] [Related]
13. Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.
Pinto C; Di Fabio F; Rosati G; Lolli IR; Ruggeri EM; Ciuffreda L; Ferrari D; Lo Re G; Rosti G; Tralongo P; Ferrara R; Alabiso O; Chiara S; Ianniello GP; Frassoldati A; Bilancia D; Campanella GA; Signorelli C; Racca P; Benincasa E; Stroppolo ME; Di Costanzo F
Cancer Med; 2016 Nov; 5(11):3272-3281. PubMed ID: 27748041
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
Lin GN; Liu PP; Liu DY; Peng JW; Xiao JJ; Xia ZJ
Chin J Cancer; 2016 Jan; 35():5. PubMed ID: 26740116
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
[TBL] [Abstract][Full Text] [Related]
16. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.
Diouf M; Bonnetain F; Barbare JC; Bouché O; Dahan L; Paoletti X; Filleron T
Oncologist; 2015 Jan; 20(1):62-71. PubMed ID: 25542450
[TBL] [Abstract][Full Text] [Related]
17. Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review.
Schuurhuizen CSEW; Braamse AMJ; Konings IRHM; Sprangers MAG; Ket JCF; Dekker J; Verheul HMW
Ann Oncol; 2017 Mar; 28(3):478-486. PubMed ID: 27998965
[TBL] [Abstract][Full Text] [Related]
18. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
Pietrantonio F; Miceli R; Rimassa L; Lonardi S; Aprile G; Mennitto A; Marmorino F; Bozzarelli S; Antonuzzo L; Tamburini E; Morano F; Rossini D; Battaglin F; Baretti M; Berenato R; Formica V; Mosconi S; Petrelli F; Ghidini M; Loupakis F; Spada D; Cinieri S; Beretta G; Falcone A; de Braud F; Cremolini C
Ann Oncol; 2017 Mar; 28(3):555-561. PubMed ID: 27864220
[TBL] [Abstract][Full Text] [Related]
19. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.
Chibaudel B; Tournigand C; Artru P; André T; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Rivera F; Perez-Staub N; Louvet C; de Gramont A
Ann Oncol; 2009 Aug; 20(8):1383-6. PubMed ID: 19465426
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
Mol L; Ottevanger PB; Koopman M; Punt CJ
Eur J Cancer; 2016 Oct; 66():138-43. PubMed ID: 27573427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]